1 / 1

Comparative Study of Intensive vs. Standard Lipid-Lowering in Treatment-Resistant Hypertension

This study examines the cumulative incidence of primary endpoints in patients with treatment-resistant hypertension receiving atorvastatin at doses of 10 mg and 80 mg. The primary endpoints include death from coronary heart disease (CHD), non-fatal non-procedure-related myocardial infarction (MI), resuscitation after cardiac arrest, and fatal or non-fatal stroke. The outcomes were tracked over several years, providing insights into the effectiveness of high-dose lipid-lowering therapy in reducing cardiovascular events in this patient population.

sawyer-summers
Télécharger la présentation

Comparative Study of Intensive vs. Standard Lipid-Lowering in Treatment-Resistant Hypertension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cumulative incidence of primary endpoint with intensive vs. standard lipid-lowering in treatment-resistant hypertension Atorvastatine 10 mg 30 Atorvastatine 80 mg Primary endpoint: death from CHD, non-fatal non-procedure-related MI, resuscitation after cardiac arrest ,fatal or non-fatal stroke 20 Primary outcome (%) 10 0 0 1 2 3 4 5 Follow-up (years) Bangalore et al., Eur Heart J 2014

More Related